Volume 96 Issue 1 | p. 13 | Concentrates
Issue Date: January 1, 2018

Start-up Jnana eyes transport proteins

By Ryan Cross
Department: Business
Keywords: Drug discovery, Jnana, SLC, solute carriers

Jnana Therapeutics has launched with $50 million in series A funding to discover small molecules that target a family of membrane proteins called solute carriers (SLCs). “Only a handful” of more than 400 SLC proteins have been tapped as drug targets, Jnana CEO Amir Nashat says. SLCs are important for transporting nutrients and drugs across cell membranes; Jnana’s first programs will focus on ones implicated in immuno-oncology, inflammation, and neurological disease. Jnana’s founders include Harvard University chemist Stuart Schreiber.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment